Close Menu

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a distribution deal for its SelectMDx for Prostate Cancer test in Spain with pharmaceutical company Ferrer.

Under the terms of the five-year exclusive deal, 10 Ferrer sales representatives will sell SelectMDx directly to 1,000 urologists in Spain. Samples will be sent to MDxHealth's laboratory in Nijmegen, the Netherlands for analysis. The agreement takes effect in January 2018.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.